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AbsTrACT
Objective GO-COLITIS aimed to measure the 
effectiveness of subcutaneous golimumab in tumour 
necrosis factor-α antagonist–naive patients with moderate 
to severe ulcerative colitis (UC) despite conventional 
treatment.
Design GO-COLITIS was an open label, single arm, 
phase 4 study with a pragmatic design which reflected 
UK clinical practice. Adult patients were eligible if 
diagnosed with UC ≥3 months, partial Mayo score 
(PMS) 4–9. Patients received subcutaneous golimumab 
induction (200 mg initially and 100 mg at week 2) 
followed at week 6 by 50 mg or 100 mg (depending on 
weight) every 4 weeks until week 54 with a 12-week 
follow-up. Efficacy was measured by PMS at baseline, 
week 6, 30, 54 and 66. Health-related quality of life 
(HRQoL; Inflammatory Bowel Disease Questionnaire 
(IBDQ) and EuroQol Group 5 Dimensions Health 
Questionnaire (EQ-5D)) was assessed at baseline, week 
6 and week 54. All safety adverse events (AEs) were 
recorded.
results 207 patients were enrolled and 205 received 
golimumab (full analysis set (FAS)205). At week 6, 
68.8% (95% CI 62.0% to 75.1%) and 38.5% (95% CI 
31.8% to 45.6%) of patients were in response and 
remission, respectively, using PMS. At the end of the 
induction phase, 140/141 patients in clinical response 
continued into the maintenance phase (Maintenance 
FAS). Sustained clinical response through week 54 was 
achieved in 51/205 (24.9%) of the FAS205 population 
and 51/140 (36.4%) of the Maintenance FAS population. 
Statistically significant improvements from baseline to 
week 6 were observed for the IBDQ total score and for 
each IBDQ domain score (bowel symptoms, emotional 
function, systemic symptoms and social function), as 
well as the EQ-5D index score and associated visual 
analogue scale score (p<0.0001). Improvement of 
HRQoL was sustained through week 54. Serious AEs 
leading to treatment discontinuation occurred in 8.8% 
of patients.
Conclusion In this study measuring patient-reported 
outcomes in patients with moderate to severe UC, 
golimumab induced and maintained response as 
measured by PMS and significantly improved quality of life 
measures.
Trial registration number NCT02092285; 2013-004583-
56.
IntroductIon
Ulcerative colitis (UC) is a chronic inflamma-
tory disease characterised by inflammation 
of the colon with increased stool frequency 
and rectal bleeding. Conventional thera-
pies, including mesalazine, corticosteroids, 
immunomodulators and surgery are estab-
lished treatments of UC. However, there 
remains an unmet need for sustained disease 
control preventing bowel damage and colec-
tomy while improving patients’ quality of 
life (QoL).1The antitumour necrosis factor 
(TNF) therapies with infliximab, adalim-
umab and golimumab have been approved 
for the treatment of moderately to severely 
active UC in adults.2 Early response to induc-
tion and mucosal healing with infliximab are 
associated with long-term benefit and lower 
colectomy rates.3 
Treatment with subcutaneous (SC) golim-
umab, a human monoclonal anti-TNF anti-
body, was approved in the European Union) 
based on two phase 3 clinical studies 
(Programme of Ulcerative colitis Research 
Studies Utilising an Investigational Treatment 
(PURSUIT)-SC, a 6-week SC induction study 
and PURSUIT-Maintenance (PURSUIT-M), 
a 54-week SC maintenance study), which 
demonstrated the efficacy and safety of 
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golimumab subcutaneous injection in moderately to 
severely active patients with UC who were refractory to or 
intolerant of conventional UC therapies.4 5
GO-COLITIS was an open-label, single-arm, phase 
4 study reflecting clinical practice in the UK aimed at 
assessing the efficacy and safety of golimumab in inducing 
and maintaining clinical response and improving QoL 
over 54 weeks in patients with moderate to severe UC.
Methods
Patients
GO-COLITIS was conducted in 29 UK centres. Eligible 
patients (≥18 years) had UC for ≥3 months, a diagnosis 
of moderate to severe disease at baseline (defined as 
Partial Mayo Score (PMS) 4–9), were anti-TNF naive and 
had a baseline rectal bleeding subscore ≥1. All patients 
received golimumab induction treatment according to 
the Summary of Product Characteristics (ie, they had 
responded inadequately to, had failed to tolerate or 
had medical contraindications for conventional therapy, 
defined as azathioprine/6-mercaptopurine and cortico-
steroids).6 Responders to induction entered the 54-week 
maintenance phase. Exclusion criteria were prior surgery 
for UC or likely need for surgery during the study, isch-
aemic or fulminant colitis, toxic megacolon, pathogenic 
bowel infection, inflammatory bowel disease (IBD) 
unclassified, evidence of Crohn’s disease, UC confined 
to proctitis (distal 15 cm or less) or treatment within 2 
weeks of study inclusion with rectal corticosteroids or 
5-aminosalicylates (5-ASAs). Stable dosing of 5-ASAs and 
corticosteroids was required for ≥2 weeks before base-
line and for ≥4 weeks before baseline for azathioprine or 
6-mercaptopurine. Patients could be discontinued from 
the study for any reason and were not to be replaced; 
mandatory discontinuations were made for patients 
meeting the criteria for treatment failure (lack of ther-
apeutic effect, prohibited change in UC medication, 
formation of a stoma or colectomy). All patients provided 
written informed consent.
study design and treatment
During the 6-week golimumab induction phase, patients 
received SC golimumab on day 0 (200 mg) and day 14 
(100 mg). Those responding to induction, assessed 
by PMS change from baseline at week 6, were eligible 
to receive maintenance SC golimumab 50 or 100 mg 
(dependent on body weight as per SmPC) every 4 weeks 
(Q4W)±5 days, for a total of 54 weeks of treatment, with 
a 12-week follow-up at the Investigator’s discretion. Dose 
adjustment was not allowed.
study evaluations
Disease activity was assessed at screening, baseline, week 
6, 30, 54 and 66 using PMS. Clinical response was defined 
as a decrease in PMS of ≥2 points and ≥30% from base-
line, plus either a decrease in the rectal bleeding subscore 
of ≥1 point or an absolute rectal bleeding subscore of 0 
or 1. Clinical remission was defined as a PMS ≤2 and no 
individual subscore >1. Data for endoscopy was collected 
whenever the procedure was performed; however, endos-
copy was not mandated.
Health-related quality of life (HRQoL) was assessed at 
baseline, week 6 and week 54 using IBDQ and EuroQol 
Group 5 Dimensions Health Questionnaire (EQ-5D).7 8 
Routine laboratory assessments were made at baseline, 
week 6, 30 and 54. All adverse events (AEs) were recorded 
at study visits.
data analysis
The primary endpoint of GO-COLITIS was the propor-
tion of patients maintaining a clinical response (ie, 
sustained clinical response) through week 54, as assessed 
by PMS measured at weeks 6, 30 and 54. Secondary 
endpoints included clinical response at week 6, response 
and remission rates at week 54, proportion of patients 
with normal QoL (defined as IBDQ score >170), change 
in HRQoL from baseline at week 6 and 54) and safety.
A sample size of 200 patients was calculated to provide a 
95% CI for the induction response rate of 43%–57% and 
for the overall 1 year sustained response rate of 19%–32% 
based on the PURSUIT trial results.4 5
Efficacy and HRQoL were assessed for all patients 
(full-analysis set (FAS)). Safety was assessed for all 
summary box
What is already known about this subject?
 ► The randomised, placebo-controlled Programme of Ulcerative colitis 
Research Studies Utilising an Investigational Treatment (PURSUIT) 
studies demonstrated the efficacy of golimumab in inducing and 
maintaining continuous clinical response over 54 weeks.
What are the new findings?
 ► Efficacy and safety of golimumab in moderate to severe ulcerative 
colitis (UC) is confirmed in this large (n=205) study whose prag-
matic design reflected clinical practice in the UK. Early response 
to golimumab induction was higher, but sustained response in the 
induction responders was lower compared with the randomised 
controlled PURSUIT trials. Overall, 1-year sustained response rates 
in PURSUIT-M and GO-COLITIS are similar for the full analysis set, 
despite very different trial designs.
 ► Well-executed observational real-world UC studies are needed to 
translate the findings of complex randomised controlled registration 
trials into clinical practice.
How might it impact on clinical practice in the foreseeable 
future?
 ► GO-COLITIS assessed golimumab effectiveness by partial Mayo 
score, quality of life, and safety analysis. Patient-reported stool fre-
quency and rectal bleeding can be used to monitor disease activity 
in moderate to severe UC.
 ► The results of GO-COLITIS support the use of golimumab as per its 
European Medicines Agency indication: for treatment of moderately 
to severely active UC in adult patients who have had an inadequate 
response to conventional therapy including corticosteroids and 
6-mercaptopurine or azathioprine or who are intolerant to or have 
medical contraindications for such therapies.
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enrolled patients who received at least one golimumab 
injection. Patients with missing PMS subscores were 
excluded from analysis of PMS change from baseline and 
treated conservatively in other analyses. Comparisons in 
the mean change from baseline in PMS, PMS subscores, 
IBDQ and EQ-5D data were made using the paired t-test. 
Factors possibly related to response outcomes were 
explored using summary statistics, graphical methods 
and logistic regression.
results
Patients
Between July 2014 and February 2015, 207 patients 
enrolled in GO-COLITIS with 205 patients receiving 
golimumab (figure 1). The median (range) age was 35 
(18–79) years; 60% of patients were male (table 1). Base-
line mean (SD) PMS was 6.4 (1.4); mean (SD) full Mayo 
Figure 1 Consolidated Standards of Reporting Trials 
diagram. *Two patients were not treated as a result of post-
consent adverse events. 
Table 1 Demographics and baseline disease 
characteristics
Characteristic All patients (n=205)
Sex, n (%)
  Female 82 (40.0)
  Male 123 (60.0)
Median (range) age, years 35.0 (18.0–79.0)
Race, n (%)
  White 166 (81.0)
  Asian 28 (13.7)
  Multiracial* 6 (2.9)
  Black or African American 5 (2.4)
Median (range) disease duration, y ears 3.9  (0.3–38.8) 
Disease extent
  Left-sided colitis 97 (47.3)
  Pancolitis (extensive) 64 (31.2)
  Unknown 44 (21.5)
Mean (SD) partial Mayo score 6.4 (1.40)
Mean (SD) full Mayo score (n=92) 8.7 (1.65)
Stool frequency score (SFS), n (%)
  SFS 0 (Normal) 3 (1.5)
  SFS 1 (1–2 stools more than normal) 16 (7.8)
  SFS 2 (3–4 stools more than normal) 64 (31.2)
  SFS 3 (≥5 stools more than normal) 122 (59.5)
Rectal bleeding score (RBS), n (%)
  RBS 0 (No blood seen)† 6 (2.9)
  RBS 1 (Streaks of blood with stool less than 
half of the time)
77 (37.6)
  RBS 2 (Obvious blood with stool most of the 
time)
94 (45.9)
  RBS 3 (Blood alone passed) 28 (13.7)
Endoscopic findings (n=92), n (%)
  Mild disease‡ 5 (5.4)
  Moderate disease§ 58 (63.0)
  Severe disease¶ 29 (31.5)
Physician global assessment (PGA), n (%)
  PGA 0 (Normal) 1 (0.5)
  PGA 1 (Mild disease) 1 (0.5)
  PGA 2 (Moderate disease) 150 (73.2)
  PGA 3 (Severe disease) 53 (25.9)
Concomitant medications, n (%)
  5-Aminosalicylates 145 (70.7)
  Azathioprine 93 (45.4)
  Corticosteroids 80 (39.0)
  6-Mercaptopurine 19 (9.3)
  Methotrexate 6 (2.9)
*Defined as have ≥2 of American Indian or Alaska native, black or 
African-American, Native Hawaiian or other Pacific islander, White or 
Asian.
†The six patients with rectal bleeding subscore 0 were included in the 
analysis; no patient selection was performed for the analysis.
‡Mild  disease = erythema , decreased vascular pattern, mild friability. 
§Moderate  disease = marked  erythema , absent vascular pattern, 
friability, erosions. 
¶Severe  disease = spontaneous  bleeding , ulceration. 
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score (FMS) (n=92) was 8.7 (1.7). Overall, 203 patients 
received both golimumab induction doses. Concomitant 
medications at baseline included 5-ASAs (70.7%), corti-
costeroids (39.0%), azathioprine (45.4%), 6-mercapto-
purine (9.3%) and methotrexate (2.9%) (table 1).
efficacy analysis
The primary analysis population for the evaluation of 
efficacy during the maintenance period was the FAS205 
consisting of patients who received at least 1 dose of goli-
mumab. Patients who were responders at week 6 and 
continued into the maintenance phase were used as a 
secondary population for evaluation of rates of clinical 
response and remission (Maintenance FAS).
clinical efficacy
In the induction phase, 68.8% (141/205, 95% CI 62.0% 
to 75.1%) and 38.5% (79/205, 95% CI 31.8% to 45.6%) 
of patients were in clinical response and clinical remission 
at week 6, respectively. At the end of the induction phase, 
140/141 patients in clinical response continued into 
the maintenance phase; one patient in clinical response 
after the remission phase did not receive maintenance 
medication. Sustained clinical response through week 
54 (primary endpoint) was achieved by 36.4% (51/140, 
95% CI 28.5% to 45.0%) of induction responders (Main-
tenance FAS population) and 24.9% (51/205, 95% CI 
19.1% to 31.4%) of all patients (FAS205 population) 
(table 2). Clinical remission was achieved by 25.7% of the 
Maintenance FAS population (36/140, 95% CI 18.7% to 
33.8%) and 17.6% (36/205, 95% CI 12.6% to 23.5%) of 
the FAS205 population.
Golimumab induction resulted in improvement from 
baseline to week 6 in PMS (mean change, –3.2; SD 2.4; 
p<0.0001; figure 2A). From baseline to week 54, mean 
PMS, stool frequency score (SFS), rectal bleeding score 
(RBS) and physician global assessment (PGA) scores 
decreased from 6.4 to 1.2, from 2.5 to 0.6, from 1.7 to 
0.2 and from 2.2 to 0.4, respectively. The proportions of 
patients with normal partial Mayo subscores of SFS, RBS 
and PGA at week 6 and week 54 were increased compared 
Table 2 Patients meeting partial Mayo score response criteria at week 6, 30 and 54
Response at FAS (n=205) n (%) (95% CI) Maintenance FAS (n=140) n (%) (95% CI)
Week 6 141 (68.8%) (62.0% to 75.1%)
Week 30 79 (38.5%) (31.8% to 45.6%) 79 (56.4%) (47.8% to 64.8%)
Week 54 52 (25.4%) (19.6% to 31.9%) 52 (37.1%) (29.1% to 45.7%)
Both weeks 30 and 54 51 (24.9%) (19.1% to 31.4%) 51 (36.4%) (28.5% to 45.0%)
FAS, full analysis set.
Figure 2 Mean (SD) change from baseline to week 6 and week 54 in partial Mayo score (A), and the proportions of patients by 
severity grade for the (B) stool frequency subscore, (C) rectal bleeding subscore and (D) physician global assessment.
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with baseline (figure 2B–D). In the Maintenance FAS 
population, 11/62 (17.7%) patients using corticosteroids 
at baseline were able to taper corticosteroids after induc-
tion and 9/62 (14.5%) were off corticosteroids at week 
54.
From baseline (n=103) and week 6 (n=87) to week 54 
(n=40), median C-reactive protein (CRP) decreased from 
5.0 to 2.0 mg/L and from 4.0 to 2.0 mg/L, respectively. 
Measurement of calprotectin level was not mandated and 
measurements from baseline are only available for seven 
patients at week 54; the data is not presented here. Among 
disease baseline characteristics tested, only disease extent 
was a significant predictor of treatment response as 
measured by PMS at week 54 (see online Supplementary 
material for results) .
At week 54, 52/140 of the Maintenance FAS popula-
tion were in clinical response and entered the 12-week 
follow-up; 21 patients continued and 31 patients discon-
tinued golimumab therapy. At week 66, 48 patients were 
in clinical response; 34.3% of the Maintenance FAS 
population and 23.4% of the FAS205 population. Of 
the patients who continued golimumab therapy, 100% 
remained in clinical response at week 66. Of the patients 
who discontinued golimumab therapy at week 54, 27/31 
patients (87.1%) maintained clinical response.
health-related quality of life
During induction, statistically significant improvements 
from baseline to week 6 were observed for IBDQ total 
score (mean increase, 45.2; p<0.0001, n=192), with 
142/195 (72.8%) patients having ≥20 point improvement 
in the IBDQ total score. At week 54, mean IBDQ (SD) 
total score in the Maintenance FAS population was 186.2 
(SD 27.1) with a mean change from baseline of 66.8 
(n=59) (table 3). Median IBDQ at week 54 was 192.0, 
indicating that over 50% of patients who completed the 
study had normal QoL at week 54. Statistically significant 
improvements from baseline to week 6 were observed for 
the EQ-5D index score (mean increase, 0.1; p<0.0001) 
and the EQ-5D health state Visual Analogue Scale score 
(mean increase, 15.6 mm; p<0.0001). At week 54, mean 
EQ-5D (SD) was 0.9 (0.2), with a mean (SD) change from 
baseline of 0.2 (0.3). Mean EuroQol-Visual Analogue 
Scale (SD) at week 54 was 76.7 (20.5), with a mean (SD) 
change from baseline of 27.8 (27.7).
safety
Treatment-emergent AEs and serious AEs were reported 
in 174 (84.9%) and 49 (23.9%) patients, respectively. 
Thirty-one of 49 serious AEs were recorded as gastro-
intestinal disorders, 28 of which were recorded as UC. 
Serious AEs leading to treatment discontinuation were 
reported in 18 patients (8.8%). Three serious AEs (1.5%) 
were reported to be treatment related; septicaemia (×2) 
and miscarriage. One patient (0.5%) died as a result of 
hospital-acquired pneumonia; causality was assessed as 
not related to study drug.
Two patients (1%) needed colectomy during the induc-
tion phase and seven patients (3.4%) during the mainte-
nance phase. Three pregnancies were reported; all three 
patients discontinued the trial.
dIscussIon
GO-COLITIS was the first pragmatically designed 
open-label study to assess the efficacy and safety of goli-
mumab SC for induction and maintenance therapy in 
patients with moderate to severe UC in the UK. At week 
6, 68.8% (95% CI 62.0% to 75.1%) and 38.5% (95% CI 
31.8% to 45.6%)%) of patients were in response and 
remission, respectively, using PMS. Sustained clinical 
response through week 54 was achieved in 24.9% of 
all patients (n=205) and 36.4% of week-6 responders 
(n=140).
Table 3 Mean (SD) change from baseline in IBDQ total score, EQ-5D and EQ-VAS at week 6 and week 54
Baseline, mean (SD) Week 6, mean (SD) Week 54, mean (SD)
Change from baseline to 
week 54 (Maintenance FAS)
IBDQ total score
  N 202 140 59 59
  Mean (SD) 115.9 (32.4) 173.4 (30.0) 186.2 (27.1) +66.8 (36.7)
  Median 111 177.0 192.0 +71.0
EQ-5D index score
  N 201 140 60 58
  Mean (SD) 0.7 (0.2) 0.8 (0.2) 0.9 (0.2) +0.2 (0.3)
  Median 0.7 0.8 1.0 +0.2
EQ-VAS
  N 195 140 59 56
  Mean (SD) 46.9 (22.6) 67.1 (23.6) 76.7 (20.5) +27.8 (27.7)
  Median 50.0 72.0 80.0 +29.0
EQ-5D, EuroQol Group 5 Dimensions Health Questionnaire; EQ-VAS, EuroQol-Visual Analogue Scale;  FAS, full analysis set; IBDQ, 
Inflammatory Bowel Disease Questionnaire.
copyright.
 o
n
 6 August 2018 by guest. Protected by
http://bmjopengastro.bmj.com/
BM
J O
pen G
astroenterol: first published as 10.1136/bmjgast-2018-000212 on 7 July 2018. Downloaded from 
6 Probert CSJ, et al. BMJ Open Gastro 2018;5:e000212. doi:10.1136/bmjgast-2018-000212
Open access 
Clinical response and remission rates in the induction 
phase of GO-COLITIS are greater than the week-6 FMS 
clinical response rate (51.0%) and remission rate (17.8%) 
observed following golimumab 200/100 mg induction 
in PURSUIT-SC.5 Several smaller real-world studies with 
golimumab in UC have also reported high response and 
remission rates. In a UK study of ‘real-world’ effective-
ness of golimumab, clinical response was achieved in 
52% (23/44) and clinical remission in 34% (15/44) of 
patients at a median of 12 weeks, with a clinical benefit 
seen in 50% of patients who underwent dose escalation.9 
Taxonera et al (n=142) reported week-8 clinical response 
and remission rate by PMS of 75.4% and 43.9%, respec-
tively, in anti-TNF naive patients with UC.10 Sustained 
clinical benefit reported by Taxonera et al at 1 year was 
57.7%, comparable with reports of 1 year response of 
63.0% by Bressler et al.11 Both Taxonera and Bressler 
studies were retrospective studies that allowed dose 
adjustment of golimumab, which increased golimumab 
persistence on drug. In Taxonera et al, 31 (22%) patients 
with secondary loss of response had dose adjustment and 
22/31 (71%) regained response to golimumab. Whereas 
in Bressler et al, dose optimisation occurred in 3.6% of 
patients. In PURSUIT-M, dose optimisation was consid-
ered treatment failure and not achieving continuous clin-
ical response. We can therefore best compare our results 
with PURSUIT-M. Higher induction response and remis-
sion rates in GO-COLITIS may be related to the use of 
PMS rather than FMS as efficacy measure at week 6. Alter-
natively, the high initial response rate may result from 
the intrinsic bias of such an open label study: however, 
patients treated in the ‘real world’ all have knowledge of 
their therapy and so the bias is no greater than in routine 
clinical care. Lower maintenance response and remis-
sion rates reported in GO-COLITIS may be related to the 
differences in study design between GO-COLITIS and 
PURSUIT-M. Close follow-up with 4-weekly clinic visits in 
the PURSUIT-M randomised controlled trial compared 
with the observational design of GO-COLITIS with only 
two clinic visits may influence outcomes. Still, overall 
51/205 (24.9%) of patients achieved sustained clin-
ical response from baseline to week 54 in GO-COLITIS 
compared with 24% (47% continuous clinical response 
in 51% responders to induction) in PURSUIT-M.
Improvements in all three domains of PMS were illus-
trated by the increased proportions of patients with 
normal scores at week 6 and week 54 compared with 
baseline, particularly for stool frequency and rectal 
bleeding subscores, the two patient-reported compo-
nents of the PMS (PRO2). PMS and PRO2 have previ-
ously been shown to perform as well as FMS to identify 
patient perceived clinical response.12 Furthermore, 
PRO2 was as accurate as PMS and FMS in monitoring 
continuous clinical response of patients in PURSUIT-M 
trial13: because PMS can accurately predict FMS, endos-
copy may not always be essential for assessment of UC 
disease activity in clinical trials.14 Endoscopy to assess 
clinical response is not a standard practice in all UK 
centres and was not required in GO-COLITIS; however, 
it is recommended by Selecting Therapeutic Targets 
in Inflammatory Bowel Disease (STRIDE) consensus 
as the objective measure of mucosal inflammation in 
UC.15 Rectal bleeding, which is associated with mucosal 
inflammation and correlates with Mayo endoscopy 
subscore, can be considered a surrogate marker of 
endoscopic activity.16
Clinical trial indices for assessing UC disease activity 
may not always align with the symptoms considered 
important by patients, such as cramping or anxiety 
related to the effects of disease activity (eg, rectal 
bleeding or incontinence),17 indicating a need for 
more patient-centred assessment of disease activity. 
In GO-COLITIS, golimumab induction significantly 
improved general and disease-specific QoL, including 
bowel symptoms, emotional function, systemic symp-
toms and social function. At week 6, 142/195 (72.8%) 
of patients exceeded the IBDQ increase cut-off (≥20 
points) previously proposed as representative of 
patient-defined improvement in an assessment of UC 
clinical endpoints.18 Fast improvement of PROs is 
important for adherence to therapy and STRIDE recom-
mends restoring QoL in patients with UC through reso-
lution of rectal bleeding and normalisation of bowel 
habit.15
No new safety signals were observed in GO-COLITIS. 
The overall incidence of AEs of 84.9% in our study is 
comparable to that reported in PURSUIT-M (72.7%). 
The incidence of serious AEs in PURSUIT-M and 
GO-COLITIS was 8.4% and 23.9%. Higher rates of AEs 
and serious AEs in GO-COLITIS may reflect the patient 
population recruited to the study.
A final observation was that of the 21 patients who 
were in response at week 54 and continued on goli-
mumab therapy after week 54; none had relapsed by 
week 66. Of the 31 who discontinued golimumab, four 
(13%) had lost response by week 66. The decision to 
stop treatment at 54 weeks may have been driven by 
National Institute for Health and Care Excellence guid-
ance which states that the requirement for continued 
therapy should be reviewed after 12 months of treat-
ment. Clinicians and patients should consider carefully 
whether to discontinue golimumab once remission is 
achieved. However, further investigation is required to 
determine the effect of golimumab withdrawal after 
1 year in patients responding to treatment.
Strengths of GO-COLITIS include the large number 
of patients (n=205), the pragmatic design and the 
dosing consistent with the product label.6 Limitations 
include the early assessment at 6 weeks, following two 
doses (200 mg and 100 mg), which may have excluded 
the so-called ‘delayed’ responders from entering the 
maintenance phase.19 Efficacy and QoL results may 
have been subject to observer bias because of the 
open-label treatment assignment. PMS measures are 
subjective: stool frequency and rectal bleeding are 
subjective for the patient, while PGA is subjective 
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for the physician. Calprotectin measurement is 
not routine practice, during follow-up, in many UK 
centres and according to STRIDE, the biomarkers 
calprotectin and CRP are adjunctive measures of 
inflammation, not a therapeutic target.15 Therapeutic 
drug monitoring is not a routine practice in the UK 
and was not measured in this study: indeed, the assay 
is still not available for clinical use. The exposure–
response relationship of golimumab in UC has previ-
ously been established.20
In conclusion, in this study patients with moderate 
to severe UC experienced meaningful improvements 
from baseline to week 6 and 54 in PMS. The observed 
improvements in generic and disease-specific QoL 
provide further evidence for the importance of 
assessing PROs in patients with UC. Golimumab treat-
ment was generally well tolerated, and no new safety 
signals were identified.
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